Sorry, you need to enable JavaScript to visit this website.
Skip to main content
LOCATION

Location Settings

North America

US -  Boston
US -  San Francisco

Oceania

NZ -  New Zealand
AU -  Brisbane
AU -  Melbourne
AU -  Sydney

Asia

TH -  Bangkok
CN -  Taipei City
KR -  Seoul
PH -  Metro Manila
MY -  Kuala Lumpur
IN -  Bangalore
CN -  Shanghai
CN -  Hong Kong

GLOBAL

English

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

North America

US -  Boston
US -  San Francisco

Oceania

NZ -  New Zealand
AU -  Brisbane
AU -  Melbourne
AU -  Sydney

Asia

TH -  Bangkok
CN -  Taipei City
KR -  Seoul
PH -  Metro Manila
MY -  Kuala Lumpur
IN -  Bangalore
CN -  Shanghai
CN -  Hong Kong

GLOBAL

English

Australia

  • Advanced medical and research infrastructure
  • Government rebate of up to 43.5% on clinical trial spend
  • Simple and fast regulatory pathways

 
Australia is a developed nation with the world's top five per capita income and the second-highest human development index globally. It performs strongly in international comparisons of quality of life, health, education, and other measures.

More than one-quarter of Australians are born overseas, and more than 10% of Australians have Asian heritage.

Australia is home to some of the world’s best medical researchers and health professionals and enjoys world-class research infrastructure equal to the US. Clinical trial capability is also of an international standard and the country is well suited to conduct complex trials that are generally focused on indications aligned with the standard of care in developed nations.

With streamlined regulatory requirements and the supportive R&D Government refund of up to 43.5% on clinical research spend, Australia has become a preferred destination for early phase clinical trials.


Importantly Australia also offers alternative recruitment potential to northern hemisphere seasonally related studies.

Recently the activity growth of biotechnology companies in Australia grew about +18%, with oncology, neurology and infectious diseases representing about half of the clinical activity.

Novotech has built strong expertise over the years in providing CRO services to biotechnology companies in Australia.

In Australia, biotechnology companies enjoy start-up timelines of around 6 to 8 weeks, from Ethics Committee (EC) submission to Therapeutic Goods Administration (TGA) approval. Furthermore, Australia has 5 of the top 50 global medical schools and is one of the leading contributors in life sciences research as measured by the H-Index.